Imuno develops precision immunotherapies using its TACTICSTM platform, which engineers antibodies that specifically bind to cancer antigens presented by MHC molecules. This targeted approach enables the creation of therapies that effectively eliminate cancer cells while preserving healthy tissue, addressing the challenge of treating hard-to-target cancers.
Funding
$350K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional cancer therapies often struggle to target intracellular antigens, leaving a significant portion of potential therapeutic targets unaddressed. Many existing immunotherapies lack the specificity needed to differentiate between cancerous and healthy tissues, leading to off-target effects and toxicity. This poses a challenge in treating hard-to-target cancers effectively and safely.
Solution
Imuno is developing a new generation of precision immunotherapies that target previously inaccessible intracellular antigens. Their TACTICS™ platform engineers antibodies with high specificity for cancer antigens presented by MHC molecules, enabling the development of therapies that selectively eliminate cancer cells while sparing healthy tissue. By combining structural epitope mapping with advanced paratope prediction, Imuno aims to create safer and more effective immunotherapies for oncology and autoimmune diseases. The platform focuses on developing TCRmimic (TCRm) antibodies that exhibit unparalleled specificity and safety, eliminating cross-reactivity and maximizing therapeutic potency.
Target Audience
Imuno's primary target audience includes pharmaceutical companies and research institutions focused on developing novel immunotherapies for cancer and autoimmune disorders.
Features
- TACTICS™ platform for engineering highly specific TCRm antibodies
- Targets peptide-HLA (pHLA) antigens derived from intracellular proteins
- Structural epitope mapping for precise antigen recognition
- Advanced paratope prediction to optimize antibody binding
- Minimized cross-reactivity to reduce off-target effects
- Development of immunotherapies for oncology and autoimmune diseases